# Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases

> **NCT06888817** · PHASE3 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 408 (estimated)

## Conditions studied

- Radiation Necrosis
- High Grade Glioma (III or IV)
- Brain Metastasases
- Radiation Toxicity
- Radiation Effect
- Radiation Injury
- Radiation Injuries

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06888817
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-19
- **Primary completion:** 2028-07
- **Final completion:** 2030-07
- **Target enrollment:** 408 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06888817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06888817, "Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06888817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*